New insights into the genetics of schizophrenia

In the complex landscape of mental health research, a new peer-reviewed viewpoint offers a critical examination of how genes and environment conspire to influence schizophrenia risk. Published in Genomic Psychiatry (ISSN: 2997-2388, Genomic Press, New York), this thought-provoking analysis by researchers Natassia Robinson and Sarah E. Bergen from Karolinska Institutet in Stockholm, Sweden, brings together cutting-edge findings from genetics and epidemiology.

MeiraGTx’s stock rises on small Parkinson’s gene therapy dataset

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 16, 2024

Pα+ Mini Interview with Ester Kincová and Steve Rolles: Regulating the Non-Medical Use of Psychedelics – Psychedelic Alpha

In last week’s policy-focused Bulletin (149) we covered the publication of Transform Drug Policy Foundation’s 124-page guide, How to Regulate Psychedelics. Shortly after its publication,

November 20, 2023

Preeclampsia Can Be Fatal. New Blood Tests Aim to Determine Who Is at Risk.

When patients are expecting a baby, they hope nothing goes wrong. But at least one in 20 people who are pregnant develop preeclampsia, a high

June 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.